Welcome to our dedicated page for Urogen Pharma news (Ticker: URGN), a resource for investors and traders seeking the latest updates and insights on Urogen Pharma stock.
UroGen Pharma Ltd. develops and commercializes therapies for urothelial and specialty cancers, with recurring updates centered on approved mitomycin products and its RTGel® reverse-thermal hydrogel platform. Company announcements commonly address JELMYTO for low-grade upper tract urothelial cancer and ZUSDURI for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, including product revenue, reimbursement coding, physician education and real-world treatment experience.
UroGen news also covers clinical data publications, pipeline programs such as UGN-103 and UGN-501, research and development spending, debt financing, employee equity inducement grants and investor-conference participation. The company’s updates connect commercial execution with sustained-release local therapy designed to increase urinary tract tissue exposure to medication.
UroGen Pharma (Nasdaq: URGN) reported updated Phase 3 ENVISION results for ZUSDURI in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Among patients achieving complete response at three months (79.6%), Kaplan-Meier analysis showed a 64.5% 36-month duration of response; median DOR was not reached at 35.5 months’ follow-up and responses occurred without maintenance therapy.
UroGen Pharma (Nasdaq: URGN) announced participation in three investor conferences in May 2026: Bank of America Health Care Conference (May 13, 11:15 AM ET, Las Vegas), HC Wainwright BioConnect (May 19, 10:30 AM ET, New York), and TD Cowen Oncology Innovation Summit (May 26, 10:30 AM ET, virtual).
Webcasts will be available on UroGen’s Investor Relations website and replayed for approximately 90 days.
UroGen (Nasdaq: URGN) reported Q1 2026 results: $51.0M total revenue and $29.2M in ZUSDURI sales. ZUSDURI grew 109% quarter-over-quarter; JELMYTO generated $21.7M (+7% YoY). Net loss narrowed to $23.6M and cash totaled $140.3M.
The company expects an NDA submission for UGN-103 in H2 2026, UGN-501 IND submission in Q2 2026, and reiterated 2026 JELMYTO guidance of $97M–$101M.
UroGen Pharma (Nasdaq: URGN) will report first quarter 2026 financial results on Wednesday, May 6, 2026, prior to the market open. A live audio webcast and conference call will follow at 10:00 AM Eastern Time.
According to the company, the public webcast is accessible via its Investor Relations website and a replay will be available on the site for approximately 30 days.
UroGen (Nasdaq: URGN) launched the LG-UTUC Luminaries initiative on April 8, 2026 to recognize clinicians and institutions showing leadership in low-grade upper tract urothelial cancer care.
The program highlights guideline-aligned, kidney-sparing approaches and names Dr. Saum Ghodoussipour as the inaugural honoree.
UroGen (Nasdaq: URGN) announced publication in The Journal of Urology of Phase 3 ENVISION results for ZUSDURI (mitomycin) for recurrent low‑grade intermediate‑risk non‑muscle invasive bladder cancer.
Key data: 24‑month event‑free probability 72.2% after three‑month complete response (CR rate 79.6%; 95% CI: 64%, 79%), median follow‑up 23.7 months, median duration of response not reached. Safety: common adverse reactions ≥10% and serious adverse reactions in 12% (urinary retention 0.8%, urethral stenosis 0.4%). ZUSDURI is the first FDA‑approved therapy for recurrent LG‑IR‑NMIBC.
UroGen (NASDAQ:URGN) applauded BCAN's New Faces of Bladder Cancer report, a national survey of more than 1,100 patients highlighting recurrence burden and procedural load.
Key findings: nearly 80% fear recurrence (over 90% for patients under 50), women 86%, retained-bladder patients 87%, many report five or more cystoscopies and some report more than 15 procedures.
UroGen (Nasdaq: URGN) announced inducement restricted stock unit grants to 11 new employees on March 6, 2026. Up to 51,200 ordinary shares may be issued upon vesting. RSUs vest equally over three years (one-third annually) and are governed by UroGen's 2019 Inducement Plan.
The grants were made as inducements pursuant to Nasdaq Listing Rule 5635(c)(4) to support commercialization of JELMYTO and ZUSDUR and continued pipeline development.
UroGen (Nasdaq: URGN) reported full-year 2025 revenue of $109.8M, driven by ZUSDURI launch and JELMYTO sales, and announced the permanent J Code (J9282) effective Jan 1, 2026 to support reimbursement.
The company closed an amended loan with Pharmakon providing a $200M initial tranche and an optional $50M tranche, reported 2025 net loss of $153.5M, and held $120.5M in cash and securities at year-end.
UroGen (Nasdaq: URGN) entered an amended senior secured term loan with funds managed by Pharmakon on Feb 26, 2026, providing up to $250 million in two tranches.
The first tranche of $200 million funded at closing refinances an existing $125 million facility, sets a fixed 8.25% interest rate, allows a discretionary $50 million draw through June 30, 2027, has no financial covenants, and schedules repayment in four equal quarterly payments beginning Q1 2030.